Aura Reports Phase 2 End Of Study Results Evaluating Bel-sar As First-Line Treatment For Early-Stage Choroidal Melanoma; Says Bel-sar Showed 80% Tumor Control Rate, 90% Visual Acuity Preservation & Highly Favorable Safety Profile
Portfolio Pulse from Benzinga Newsdesk
Aura Biosciences reported positive Phase 2 results for Bel-sar as a first-line treatment for early-stage choroidal melanoma, showing an 80% tumor control rate, 90% visual acuity preservation, and a highly favorable safety profile.
September 12, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aura Biosciences' Phase 2 results for Bel-sar indicate strong efficacy and safety as a first-line treatment for early-stage choroidal melanoma, potentially boosting investor confidence.
The positive Phase 2 results for Bel-sar, showing high tumor control and visual acuity preservation, are likely to enhance investor confidence in Aura Biosciences. This could lead to a short-term increase in stock price as the market reacts to the potential of Bel-sar as a viable treatment option.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100